Regulation of the reserch and development of cellular drugs: the experience of the European Union and the United States


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the European Union and the United States, regulation of cell-based products for the placing on the market is rather extensive and multi-tiered. This is due to the complexities which emerge at the different steps of the process, e. g. when obtaining source materials (live human cells), further development, manufacturing and clinical investigation, as well as due to risks posed by cellular products for the patient and other people. In this paper we address foreign regulatory systems for products containing live cells as an active ingredient in order to establish the difference with the domestic system.

Full Text

Restricted Access

About the authors

R. R Niyazov

Center for scientific consulting LLC

Email: pippin.2k@gmail.com

M. A Dranitsyna

Center for scientific consulting LLC

Email: pippin.2k@gmail.com

I. E Yasny

Inbio Ventures

Email: pippin.2k@gmail.com

E. V Gavrishina

Center for scientific consulting LLC

Email: pippin.2k@gmail.com

A. N Vasiliev

Center for scientific consulting LLC

Email: pippin.2k@gmail.com

References

  1. European Parliament, Council of the European Union. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. EUR-Lex: Access to European Union law. [Online] July 18, 2009. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1565510 251540&uri=CELEX:02004L0023-20090807.
  2. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components.. EUR-Lex: Access to European Union law. [Online] July 18, 2009. [Cited: August 11, 2019.] https://eur-lex.europa.eu/legal-content/ EN/TXT/?qid=1565508720678&uri=CELEX:02002L0098-20090807.
  3. European Commission. Commission Directive 2004/33/ EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. EUR-Lex: Access to European Union law. [Online] January 9, 2015. [Cited: October 26, 2019.] https://eur-lex. europa.eu/legal-content/EN/TXT/?qid=1572099895711&uri=CELEX:0 2004L0033-20150109.
  4. Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. EUR-Lex. [Online] December 17, 2012. [Cited: October 18, 2019.] https://eur-lex.europa. eu/legal-content/EN/TXT/?qid=1571409314568&uri=CELEX:320 06L0017.
  5. UK Human Tissue Authority. Official website of the UK Human Tissue Authority. [Online] [Cited: September 23, 2019.] https://www.hta.gov. uk/.
  6. UK Human Fertilisation and Embryology Authority. Official Website of the UK Human Fertilisation and Embryology Authority. [Online] [Cited: September 23, 2019.] https://www.hfea.gov.uk/.
  7. European Directorate for the Quality of Medicines & HealthCare. Official Website of the European Directorate for the Quality of Medicines & HealthCare. [Online] [Cited: September 24, 2019.] https://www.edqm.eu/.
  8. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research. Official website of the U.S. Food and Drug Administration. [Online] July 10, 2019. [Cited: October 26, 2019.] https:// www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/ center-biologics-evaluation-and-research.
  9. Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception. Official Website of the U.S. Food and Drug Administration. [Online] November 16, 2017. [Cited: September 24, 2019.] https://www.fda.gov/media/89920/ download.
  10. О биомедицинских клеточных продуктах (с изменениями на 3 августа 2018 года). Электронный фонд правовой и нормативнотехнической документации «Консорциум «Кодекс». [В Интернете] 3 август 2018 г. [Цитировано: 15 октбяря 2019 г.] http://docs.cntd.ru/ document/420361 525.
  11. European Parliament, Council of the European Union. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. EUR-Lex: Access to European Union law. [Online] July 26, 2019. [Cited: October 26, 2019.] https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1 57210 8201015&uri=CELEX:02007R1394-20190726
  12. Об обращении лекарственных средств (с изменениями на 2 августа 2019 года). Электронный фонд правовой и нормативно-технической документации «Консорциум «Кодекс». [Online] августа 2, 2019. [Cited: октября 26, 2019.] http://docs.cntd.ru/document/902209774t
  13. Medicines and Healthcare Products Regulatory Agency. Nonroutine guidance on ATMPs. Official website of the Medicines and Healthcare Products Regulatory Agency. [Online] 2015. [Cited: October 17, 2019.] https://assets.publishing.service.gov.uk/government/uploads/system/ uploads/attachment_data/file/397739/Non-routine_guidance_on_ ATMPs.pdf.
  14. Medicines and Healthcare products Regulatory Agency. Guidance on the UK’s arrangements under the hospital exemption scheme. Official website of the Medicines and Healthcare products Regulatory Agency. [Online] 2015. [Cited: October 17, 2019.] https://assets.publishing.ser-vice.gov.uk/government/uploads/system/uploads/attachment_data/ file/397738/Guidance_on_the_UK_s_arrangements_under_the_hospi-tal_exemption_scheme.pdf.
  15. Ниязов Р.Р., Драницына М.А., Васильев А.Н. и др. Разрешение на производство лекарств и GMP: регуляторные системы России и ЕС. Новости GMP 2020. https://gmpnews.ru/2020/02/razreshenie-na-proizvodstvo-lekarstv-i-gmp-regulyatornye-sistemy-rossii-i-es/
  16. Ниязов Р.Р., Драницына М.А., Васильев А.Н. и др. Регулирование разработки, производства и вывода на рынок радиофармацевтических препаратов в России и ЕАЭС. Новости GMP 2020. https://gmpnews. ru/2020/02/regulirovanie-razrabotki-proizvodstva-i-vyvoda-na-rynok-rfp-v-rossii-i-eaes/
  17. European Commission. Commission Regulation (EC) No 668/2009. Eudralex, Volume I, Pharmaceutical legislation for medicinal products for human use. [Online] July 25, 2009. [Cited: October 17, 2019.] https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/ reg_2009_668Zreg_2009_668_en.pdf.
  18. European Commission and European Medicines Agency. European Commission-DG Health and Food Safety and European Medicines Agency Action Plan on ATMPs. Official website of the European Commission. [Online] 2017. [Cited: October 17, 2019.] https://www.ema.europa.eu/en/ documents/other/european-commission-dg-health-food-safety-european-medicines-agency-action-plan-advanced-therapy_en-0.pdf.
  19. Вульф М.А., Юрова К.А., Скуратовская Д.А., Литвинова Л.С. Законодательное регулирование и использование генетической информации в РФ и за рубежом. Гены и клетки 2019; XIV(4): 82-7.

Copyright (c) 2020 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 85657 от 21.07.2023 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies